Allison Luo, M.D., is an experienced biotech executive who has successfully led many clinical programs. Most recently, she served as Chief Medical Officer of Prometheus Biosciences from August 2018 through the company’s sale to Merck in 2023.

Prior to that, she served as CMO of Oppilan Pharma and Escalier Pharma and as SVP of Clinical Development for Gastroenterology at Progenity Inc. Before that, Dr. Luo was VP of Clinical Development at Ophthotech Corp., now Iveric bio, Inc. From 2006 to 2014, Dr. Luo was an Executive Director at Bristol-Myers Squibb Company where she was responsible for inflammatory bowel disease and led the Phase 3 program for Orencia® (abatacept) and the Phase 2 programs for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career, Dr. Luo was a Medical Director at Abbott Laboratories, where she submitted the Japanese NDA for Humira®(adalimumab) in rheumatoid arthritis and developed the clinical trial protocols for Humira in ulcerative colitis.

Dr. Luo holds a B.S. in Biochemistry and an M.D. from Northwestern University.